HyperMed Imaging, Inc. With a proven track record since 2006, our pioneering technology has been extensively used in published clinical research to effectively assess oxyhemoglobin, deoxyhemoglobin, and oxyhemoglobin saturation in superficial tissue for various healthcare applications. We are proud to introduce our new product, HyperView™, which utilizes the same breakthrough imaging technology as our OxyVu™-1 system.

HyperView™ is specifically designed to provide the same diagnostic information in a smaller, more portable configuration, ultimately setting a new standard of care. Our technology, which includes 34 issued patents and over 40 pending worldwide, uses a proprietary form of hyperspectral imaging to offer a novel and patented solution for superficial tissue oximetry. As evidence of our commitment to quality and safety, HyperView™ is FDA 510(k) cleared.

Trust HyperMed for advanced portable imaging and the assessment of tissue health